Rate My Professor Weei-Chin Lin

As a physician-scientist, Lin's research centers on cell cycle regulation, DNA damage response, protein modifications, and the development of novel cancer therapeutics, with a particular emphasis on deregulated pRb/E2F and p53 pathways in oncogenic activation. Her laboratory translates fundamental discoveries into targeted cancer therapies. Key publications include "Mutant p53 variants differentially impact replication initiation and activate cGAS-STING to affect immune checkpoint inhibition" (Communications Biology, 2025), "A small-molecule inhibitor of TopBP1 exerts anti-MYC activity and synergy with PARP inhibitors" (Proceedings of the National Academy of Sciences, 2023), "DNA2 nuclease inhibition confers synthetic lethality in cancers with mutant p53 and synergizes with PARP inhibitors" (Cancer Research Communications, 2023), "Super-enhanced MARCO variant drives triple-negative breast cancer progression" (Proceedings of the National Academy of Sciences, 2022), and "14-3-3τ drives estrogen receptor loss via ERα36 induction and GATA3 inhibition in breast cancer" (Proceedings of the National Academy of Sciences, 2022). Lin holds patents such as U.S. Patent 9,636,323 for treating TopBP1-overexpressing cancers and a pending patent for novel TopBP1 inhibitors. Her contributions advance strategies to overcome therapeutic resistance and promote cancer cell death.